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ABSTRACT
Introduction Smoking results in an average 10- year 
loss of life, but smokers who permanently quit before 
age 40 can expect a near normal lifespan. Pregnancy 
poses a good opportunity to help women to stop; around 
80% of women in the UK have a baby, most of whom are 
less than 40 years of age. Smoking prevalence during 
pregnancy is high: 17%–23% in the UK. Smoking during 
pregnancy causes low birth weight and increases the risk 
of premature birth. After birth, passive smoking is linked 
to sudden infant death syndrome, respiratory diseases 
and increased likelihood of taking up smoking. These risks 
impact the long- term health of the child with associated 
increase in health costs. Emerging evidence suggests that 
offering financial incentives to pregnant women to quit is 
highly cost effective.
This protocol describes the economic evaluation of a 
multi- centre randomised controlled trial (Cessation in 
Pregnancy Incentives Trial III, CPIT III) designed to establish 
whether offering financial incentives, in addition to usual 
care, is effective and cost effective in helping pregnant 
women to quit.
Methods and analysis The economic evaluation will 
identify, measure and value resource use and outcomes 
from CPIT III, comparing participants randomised to 
either usual care or usual care plus up to £400 financial 
incentives. Within- trial and long- term analyses will be 
conducted from a National Health Service and Personal 
Social Services perspective; the outcome for both analyses 
will be quality adjusted life- years measured using EQ- 5D- 
5L. Patient level data collected during the trial will be used 
for the within- trial analysis, with an additional outcome 
of cotinine validated quit rates at 34–38 weeks gestation 
and 6 months postpartum. The long- term model will be 
informed by data from the trial and published literature.
Ethics and dissemination
Trial registration number ISRCTN15236311; Pre-results 
(https:// doi. org/ 10. 1186/ ISRCTN15236311).
INTRODUCTION
Problem
Smoking is the principal preventable cause 
of cancer, with 64 000 new cases annually 
in the UK.1 Levels of smoking reflect levels 
of inequality; in 2016, in England, 7.9% of 
adults smoked in the least deprived areas 
compared with 27.2% in the most deprived 
areas.2 Lifelong smokers lose 10 years of life; 
however, smokers who quit before 40 years 
of age can expect a near to normal lifespan.3 
Levels of smoking during pregnancy are high; 
in 2010, 12% of mothers in England smoked 
throughout their pregnancy; this figure was 
13% and 15% in Scotland and Northern 
Ireland, respectively.4 Smoking during preg-
nancy is a recognised cause of low birth 
weight and increases the risk of premature 
birth by 27%.5 In addition to complications 
during pregnancy, after birth the conse-
quences of continued smoking on the child 
are substantial: passive smoking is linked to 
sudden infant death syndrome, lower respi-
ratory diseases, asthma and impaired lung 
function.5 Research shows that children in 
a house where parents or siblings smoke 
are 90% more likely to smoke themselves.6 
Around 80% of women in the UK have a 
baby,7 most of whom are less than 40 years of 
age. Pregnancy is a good opportunity to help 
women quit smoking, and also decreases the 
likelihood of the baby becoming a smoker in 
later life.6 Helping pregnant women to quit 
smoking can potentially help tackle inequali-
ties and lift families out of poverty.8 However, 
few of about 130 000 pregnant smokers in the 
UK quit. In the UK, all pregnant women are 
Strengths and limitations of this study
 ► Prospectively designed economic evaluation of 
a phase III randomised controlled trial with sites 
across the UK.
 ► Preference- based (utility) outcome measures at 
late- stage pregnancy and 6 months postpartum to 
enable decision-making.
 ► Six months postpartum follow- up is the longest we 
are aware of, making this a novel study.
 ► Lifetime extrapolation includes costs and outcomes 
for both mother and infant.
 ► Challenges relate to different smoking cessation 
service delivery at each trial site.
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offered National Health Service (NHS) smoking cessa-
tion services, with free nicotine replacement therapy 
(NRT); however, only 10% use these services and as few 
as 3% report abstinence at 4 weeks after quitting.9
Evidence
Financial incentives are becoming a popular approach to 
changing behaviour that will lead to healthier lifestyles.10 
A recent Cochrane review assessed incentives for smoking 
cessation and identified nine studies reporting results 
for pregnant women with a combined relative risk of 
2.38 (95% CI: 1.54 to 3.69) in favour of incentives. Eight 
studies were based in the USA, and one in the UK. The 
UK study was a single site study (Cessation in Pregnancy 
Incentives Trial II, CPIT II), which found that offering 
financial incentives helped pregnant women in Glasgow, 
Scotland, to quit.11 CPIT II estimated a cost per quality 
adjusted life- year (QALY) of less than £500, which is 
considered to be highly cost effective.12
Aim
CPIT III evaluates whether the favourable findings from 
CPIT II can be replicated in further UK sites, and includes 
an additional follow- up at 6 months postpartum. The 
CPIT III main study protocol is published elsewhere.13 
The aim of the economic evaluation described here is 
to explore the cost effectiveness of including financial 
incentives alongside usual care to increase the quit rate of 
pregnant women who smoke.
METHODS AND ANALYSIS
The main randomised controlled trial (CPIT III)
CPIT III is a multicentre randomised controlled trial, 
which aims to assess the effectiveness and cost effective-
ness of adding financial incentives to usual care to increase 
the smoking cessation rate among pregnant women. The 
primary outcome is smoking at 34–38 weeks gestation, 
self- reported, with those reporting as quit undertaking 
urine or saliva confirmatory biochemical testing. The 
secondary outcomes comprise: engaging with smoking 
cessation services and setting a quit date; smoking cessa-
tion at 4 weeks after quit date and 6 months postpartum 
(with those reporting as quit confirmed by biochemical 
testing); continuous abstinence from late pregnancy to 
6 months postpartum; birth weight; cost effectiveness and 
process evaluation.
Participants are pregnant women who self- report as 
smokers, are 16 years or older, less than 24 weeks pregnant 
and English speaking. The target recruitment number 
was 940, to give 90% power and 5% significance to show a 
doubling of quit rate from 7% in the control arm to 14% 
with financial incentives, allowing 15% loss to follow- up. 
The estimate of 7% in the control arm was derived from 
CPIT II (8.6% abstinent)11 and two other recent large 
trials of pregnancy cessation interventions, conducted in 
regions where CPIT III will recruit: abstinent 6.4%14 and 
7.6% .15 The average control group abstinence rate was 
7.5% at late pregnancy. The estimate of 14% in the inter-
vention arm is based on both the cessation rate in CPIT 
II (22.5%) plus a reflection of what is considered clini-
cally important. A gain of 7%–14% would be considered 
clinically important and is comparable to pharmaceu-
tical aids in non- pregnant smokers.16 Assuming partici-
pants with missing smoking status are smoking as per the 
Russell Standard,17 the attrition rate would be 0%, and as 
a result 940 participants would give 94% power to detect 
a doubling of the quit rate from 7% to 14%.
944 participants were recruited from seven sites in 
England, Scotland and Northern Ireland between 
February 2018 and April 2020. Pregnant smokers iden-
tified at routine maternity booking appointments who 
were referred to smoking cessation services were assessed 
for eligibility. The trial was introduced to eligible women 
at first routine contact with smoking cessation services. 
Those interested in taking part were sent a participant 
information sheet and contacted by telephone after at 
least 5 days to obtain formal consent. Those consenting 
were randomised to either receive financial incentives 
plus usual smoking cessation support or usual smoking 
cessation support only. The incentives are presented in 
table 1.
Both groups will be offered local smoking cessation 
support and a research participation voucher. This shop-
ping voucher for £50 is issued if data is provided for 
Table 1 Intervention and research participation incentives
Time point Intervention Control
Initial local smoking cessation services 
meeting and setting quit date
£50 voucher N/A
Verified quit at 4 weeks after quit date £50 voucher N/A
Verified quit at 12 weeks after quit date £100 voucher N/A
Verified quit at 34–38 weeks gestation 
and provision of urine/saliva sample if 
quit
£200 voucher N/A
Providing data for primary outcome £50 voucher for research participation £50 voucher for research participation
Providing data for secondary outcome 
(quit 6 month postpartum)
£25 voucher for research participation £25 voucher for research participation
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the primary outcome in late pregnancy and a further 
£25 shopping voucher issued if data is provided for the 
secondary outcome at 6 months postpartum. Participants 
can still receive the £25 shopping voucher if they provide 
data for the secondary outcome but do not provide data 
for the primary outcome.
Participants in the intervention arm will also receive up 
to £400 in shopping vouchers, £50 for attending an initial 
appointment with local smoking cessation services and 
setting a quit date, £50 if verified quit at 4 weeks after quit 
date, £100 if verified quit at 12 weeks after quit date and 
£200 if verified quit and provide a saliva/urine sample 
at 34–38 weeks gestation (primary outcome point). All 
incentive payments, apart from the first, require quit to be 
verified by carbon monoxide (CO) breath test. Cotinine/
anabasine will also be used to confirm non- smoking status 
at the primary outcome and 6 months postpartum. Partic-
ipants in the incentives group not attending smoking 
cessation services can still receive the final £200 shop-
ping voucher if they are CO verified quit at the primary 
endpoint of 34–38 weeks gestation and provide a saliva/
urine sample.
Further details on the CPIT III are detailed in the main 
study protocol paper, which is available elsewhere.13
The economic evaluation
The economic evaluation will be conducted from the 
perspective of the UK’s NHS and Personal Social Services 
(PSS), including only resources funded by the NHS, and 
include costs for the price year 2020.
Two analyses will be carried out: a within- trial analysis 
and a long- term lifetime analysis. The within- trial results 
will be presented as an incremental cost per quitter and 
an incremental cost per QALY gained. The lifetime 
model results will be reported as incremental cost per 
QALY gained. For both analyses, results will be assessed 
against the current National Institute for Health and 
Care Excellence (NICE)threshold of £20 000–£30 00018 
per QALY gained. The economic evaluation will adhere 
to best practice and guidelines.19 20
An overview of this analysis is illustrated in figure 1. The 
participants (pregnant smokers) are randomised to either 
the intervention or control arm. The primary outcome of 
the trial is quit at 34–38 weeks gestation and both this trial 
primary outcome and the economic outcome of QALYs 
will be used in the cost- effectiveness analysis.
The analysis will be conducted using the statistical anal-
ysis package STATA V.16 (StataCorp LLC, 2019, Stata 
Statistical Software: Release 16, College Station, Texas, 
USA).
Within-trial analysis
Patient level data on resource use and outcomes will 
be routinely collected during the trial and used in the 
economic evaluation. The time horizon for the within- 
trial analysis is that of the trial, from time of maternity 
booking (less than 24 weeks gestation) to late pregnancy 
(34–38 weeks gestation) and 6 months postpartum. No 
discounting of costs and outcomes is required as this time 
horizon is less than 1 year. The analysis will be undertaken 
based on an intention to treat approach, and participants 
lost to follow- up will be assumed to be smokers.
Resource use
There are four main resource use groups of relevance 
informing the within- trial analysis: smoking cessation 
support (professional time), NRT, intervention costs 
(financial incentives) and neonatal care. Methods of data 
collection for these resource use categories are described 
in the following section.
Service delivery of smoking cessation support and 
prescribing of NRT is likely to vary between trial sites. 
Health economists will work with each site to establish 
the format of the service delivered at that site, and set 
up and maintain resource use data collection procedures. 
To date, methods used for collecting resources include 
routinely collected NHS data and bespoke Excel spread-
sheets. Resource data for the cessation services will typi-
cally be around 12 weeks’ worth of NRT and cessation 
support from first contact with cessation services to last 
contact.
The trial data management system will record when 
shopping vouchers are sent to participants and a stan-
dard postal cost will be assigned to each voucher posted. 
Vouchers are sent at first consultation, 4 weeks and 12 
weeks after quit, late pregnancy (34–38 weeks) and 
6 months postpartum (see table 1). Resource use in terms 
of shopping vouchers will be recorded at each follow- up 
point, up to and including 6 months postpartum.
The child’s birth weight and date of delivery will be 
collected postpartum via the trial data management 
system, enabling preterm status to be derived. Assump-
tions will be made about the levels of neonatal care 
required based on this birth weight and prematurity/
preterm status.
Unit costs
Unit costs will be obtained from routine sources:
 ► British National Formulary—NRT.21
Figure 1 Decision tree, including intervention and 
outcomes.
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 ► PSS Research Unit—smoking cessation advisor/
pharmacist.22
 ► Trial data management system—shopping vouchers/
postage.
 ► NHS reference costs, Information Services Division 
NHS Scotland, and the literature—neonatal costs.
Costs will be for the price year 2020, expressed in 
pounds sterling (£) and inflated if necessary using the 
Health Services (HS) index.23 For publication in journals, 
final costs may also be presented in US dollars, converted 
using the exchange rate, so that the results will be appro-
priate for an international audience.
Unit cost information will be combined with the 
resource use data collected in the trial to estimate the 
total cost per participant in each trial arm. These partic-
ipant total costs will be aggregated to estimate the total 
cost of each trial arm and subsequently the average cost 
per participant for each intervention.
Regression analysis will be conducted to explore the 
effect that baseline variables have on the cost of each 
intervention, such as EQ- 5D- 5L score, site and gestational 
age at booking. Variables included will be in line with the 
statistical analysis plan and main analysis.
Outcomes
There will be two economic outcomes: the within trial 
quit rate and QALY.
The primary outcome of the trial is smoking status at 
34–38 weeks gestation. This indicator will inform the 
incremental cost per quitter analysis. As this is an inter-
mediate outcome and not a measure of health, we are 
also conducting a within trial incremental cost per QALY 
analysis.
The QALY is a combination of quality of life and quan-
tity of life. Quality of life will be measured using the 
EQ- 5D- 5L questionnaire,24 which measures five dimen-
sions: mobility, self- care, usual activities, pain/discomfort 
and anxiety/depression, with five levels: no problems, 
slight problems, moderate problems, severe problems 
and extreme problems. The EQ- 5D- 5L will be completed 
by participants at three time points: baseline, late preg-
nancy (34–38 weeks gestation) and 6 months postpartum.
The EQ- 5D- 5L is converted to utilities using value sets 
giving a utility value of between −0.59 and 1. A utility 
value of 1 represents full health, 0 represents death and 
between -0.59 and 0 represents a state worse than death 
(where members of the general public were asked to 
value health states using time trade off, one option was 
believed to be worse than death, ie, bowel and bladder 
incontinence). We will map the EQ- 5D- 5L results to the 
EQ- 5D- 3L UK value set25 in accordance to the recommen-
dation in the current position statement from NICE.26 27
The quantity of life element of the QALY will be the 
length of time the participant remains in the trial, using 
standard QALY calculation applying an area- under- 
the- curve approach.28 For example, for a participant 
recruited at 20 weeks gestation who has primary outcome 
data collection at 38 weeks, the calculation for a QALY 
would be as follows:
(Utility at 38 weeks gestation−utility at 20 weeks 
gestation)×38–20/52.
When combining the utility score generated from 
the EQ- 5D- 5L with quantity of life to give a QALY, stan-
dard area- under- the- curve methods29 will be employed, 
weighting utilities by the duration of each time interval. 
Any change in utility between time points will be treated 
as linear.
A regression analysis will be carried out in line with the 
main analysis and statistical analysis plan exploring the 
effect that baseline variables have on the outcomes, such 
as site, gestational age at booking and in particular base-
line utilities.28
Analysis of costs and effects
Missing health economic data will be dealt with in line 
with best practice guidance30: a descriptive analysis of the 
missing data will be carried out and assumptions will be 
made to ascertain the type of missingness; following this, 
an appropriate method for handling missing data will be 
chosen. If data is missing at random, we will use multiple 
imputation using chained equations. Finally, a sensitivity 
analysis for complete cases will be conducted and further 
sensitivity analyses will be carried out around assump-
tions as appropriate, for example, using best/worst case 
assumption scenarios and exploring unexpected issues 
arising such as COVID-19 and not being able to take 
CO monitoring readings. Any participants with missing 
outcome data will be assumed to be smokers.
The cost- effectiveness analysis will bring together the 
estimates of cost and effect as described above, by esti-
mating an incremental cost effectiveness ratio (ICER) of 
cost per quitter and per QALY. The difference between 
mean costs will be divided by the difference in mean 
QALYs and quit rates to calculate the ICER; the formula 
for this is presented below. The control arm is denoted 




The costs, QALYs and quit rates per participant in each 
trial arm (ie, the average quit rate per arm) will be pre-
sented as means and SD. Differences in means between 
trial arms will be presented with 95% CIs using gener-
alised linear models with appropriate link and family 
functions.
Uncertainty
The effect of uncertainty on the results will be explored 
using non- parametric bootstrapping techniques and the 
resulting samples will be plotted on a cost- effectiveness 
plane in order to graphically represent uncertainty.31 
Cost- effectiveness acceptability curves will then be used to 
present uncertainty in terms of willingness to pay under 
various monetary thresholds.32 Ninety- five per cent CIs 
for the ICER will be presented using the results of the 
bootstrapping. If appropriate, 95% CIs for the ICER will 
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be estimated using Fieller’s theorem, a technique that 
includes any correlation between cost and outcome.33
Any subgroup analyses deemed appropriate in the statis-
tical analysis plan will also be considered for the economic 
analysis. This will include an analysis using self- reported 
smoker/quitter extracted from case notes, where the trial 
team have not been able to establish smoking status via 
direct contact with participants.
Two sensitivity analyses will be run: using miscarriage 
data from the trial and exploring the effects of gaming 
(where the participant self- reports as a quitter but is still 
smoking) in the trial.
Long-term model
The time horizon for the long- term economic model 
is lifetime. Costs and effects will be discounted at 3.5% 
annually in line with recommendations from NICE.20
The within trial analysis only considers the costs and 
effects of the pregnant woman and neonatal costs. The 
long- term model will also include the costs and effects 
related to the child. The rationale for this is that children 
of smokers are more likely to smoke themselves and will 
also be exposed to second- hand smoke, increasing the 
likelihood of smoking- related diseases.6
Model structure
The analysis will use and adapt a published probabi-
listic decision analytic Markov model, the Economics of 
Smoking in Pregnancy (ESIP) model.34 The model will 
comprise two sections: one to capture the lifetime costs 
and outcomes for the mother, and one to capture the life-
time costs and outcomes of the child.20 The ESIP model 
was the first model specifically developed to include 
future potential cost savings and improvement in health 
for both mother and child. A short- term cost- effectiveness 
analysis can be misleading as the benefits of stopping 
smoking are not captured in a short- time horizon, which 
is why it is important to incorporate future benefits to 
assess the full impact of offering financial incentives to 
pregnant smokers.
The mother’s portion of the model will include: the 
costs of smoking cessation services, financial incentives, 
NRT use and smoking- related diseases (coronary heart 
disease, chronic obstructive pulmonary disease (COPD), 
lung cancer and stroke that account for 75% of smoking 
related deaths), plus data on relapse rates and transition 
to smoking- related diseases if the woman relapses. The 
child’s part of the model will include: costs associated at 
birth for children with smoking mothers if appropriate 
(premature birth and underweight new- borns), outcomes 
related to exposure to second- hand smoke in the home 
(ie, asthma and longer term smoking- related diseases), 
smoking uptake rates for children of smokers and associ-
ated smoking- related diseases.
The trial quit rate at 6 months after birth will be used 
to predict smoking relapse postpartum. The final utility 
estimates for patient level data from the postpartum 
follow- up will also be used as a point for extrapolation 
for lifetime analysis (rather than assuming background 
population utility values).
Figure 2 depicts the likely structure of the long- term 
model.35 The model is split between mother and infant; 
the first ‘within pregnancy’ section on the left illustrates 
within pregnancy outcomes and related costs, the middle 
‘childhood’ section depicts the infant’s childhood from 
birth to 15 years old and the last section ‘lifetime’ on the 
right depicts lifetime for both mother and infant.
Resource use and outcomes collected during the trial 
will be extrapolated and supplemented with published 
costs from the literature.
Analysis
The lifetime analysis results will be presented as cost per 
QALY gained for both the mother and child, separately 
and combined.
A probabilistic sensitivity analysis will be included and 
appropriate sensitivity analyses will explore underlying 
assumptions used in the model, including:
 ► Re- analysis to account for gaming identified.
 ► Self- reported outcomes.
 ► Varying amount of incentive.
 ► Applying alternative discount rates.
 ► Varying relapse rates.
Patient and public involvement
No patient involved.
ETHICS AND DISSEMINATION
Ethics approval was received from NHS West of Scot-
land Research Ethics Committee on 15 August 2017. 
Results of the main trial and economic evaluation will 
be disseminated through peer- reviewed publications and 
presentations.
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